Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.54 |
| ▸ | CCR5 | P51681 | 6/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7885806 | 1.00 | RORC (0.54) | RORCCCR5HTR2CDRD2DRD3 | |
| SCHEMBL7878986 | 0.91 | CCR5 (0.58) | RORCCCR5HTR2CKDM1AGBA1 | |
| SCHEMBL7889957 | 0.88 | RORC (0.55) | RORCCCR5HTR2CDRD2DRD3 | |
| SCHEMBL3035472 | 0.88 | RORC (0.55) | RORCCCR5HTR2CDRD2DRD3 | |
| SCHEMBL3035470 | 0.88 | RORC (0.55) | RORCCCR5HTR2CDRD2DRD3 | |
| SCHEMBL2820735 | 0.83 | RORC (0.58) | RORCCCR5DRD2DRD3BCHE | |
| SCHEMBL1976472 | 0.83 | RORC (0.58) | RORCCCR5HTR2CDRD2DRD3 | |
| SCHEMBL2820737 | 0.83 | RORC (0.58) | RORCCCR5DRD2DRD3BCHE | |
| SCHEMBL1202337 | 0.83 | RORC (0.58) | RORCCCR5HTR2CDRD2DRD3 | |
| SCHEMBL2226943 | 0.83 | RORC (0.58) | RORCCCR5HTR2CDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398768-B1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | disclosed |
| US-8318759-B2 | Pyrrolidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210659-A1 | PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | OPRL1, OPRK1, OPRD1 | RORC 1018/4885CCR5 1616/4885HTR2C 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.